1. World Health Organization. (2021). Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes 2. Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550-1562. 3. Atkinson, M. A., & Eisenbarth, G. S. (2001). Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet, 358(9277), 221-229. 4. American Diabetes Association. (2021). Lifestyle management: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement_1), S74-S96. 5. Zimmermann, M. B. (2009). Iodine deficiency. Endocrine Reviews, 30(4), 376-408. 6. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403. 7. Chiovato, L., Magri, F., Carlé, A., & Hypothyroidism Study Group of the Italian Thyroid Association. (2012). Thyroid autoimmunity and environment. Hormones, 11(4), 401-413. 8. American Diabetes Association. (2021). 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement_1), S15-S33. 9. American Diabetes Association. (2020). 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Supplement_1), S183-S192. 10. Blevins, T. C., & Miamoun, L. (2008). Safety of insulin glargine use in pregnancy. Endocrine Practice, 14(3), 270-275. 11. United Nations Environment Programme. (2013). State of the science of endocrine disrupting chemicals - 2012. https://www.unep.org/resources/report/state-science-endocrine-disrupting-chemicals-2012 12. World Health Organization. (2009). Health promotion glossary. https://www.who.int/healthpromotion/about/HPR%20Glossary%201998.pdf